Physician profile
Devyani Sivakumar
NPI 1285288308
$5,147.91
in general payments reported to CMS, 2019-2025
32 companies · $2,447 in 2025
The $2,447 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $151 · 2021: $353 · 2022: $581 · 2023: $239 · 2024: $1,118 · 2025: $2,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748 · Education: $57.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.75 |
| Education | $57.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $677.24 | 2019-2025 | Lokelma, Farxiga |
| Alexion Pharmaceuticals, INC. | $524.18 | 2020-2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $445.45 | 2022-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.60 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $333.45 | 2022-2025 | |
| Travere Therapeutics, INC. | $304.54 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $274.01 | 2024-2025 | Tarpeyo |
| Amgen INC. | $269.57 | 2024-2025 | Tavneos, Parsabiv, Aranesp |
| E.R. Squibb & Sons, L.L.C. | $268.92 | 2020-2023 | Camzyos |
| Fresenius USA Marketing, INC. | $165.44 | 2024-2025 | Velphoro, Velphoro |
| Pfizer INC. | $154.15 | 2019-2022 | |
| Novo Nordisk INC | $143.91 | 2025 | Ozempic, Wegovy |
| Ardelyx, INC. | $135.70 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $126.40 | 2025 | Veltassa |
| Veloxis Pharmaceuticals, INC. | $125.00 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $75.95 | 2025 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $75.85 | 2024-2025 | |
| Gilead Sciences, INC. | $74.77 | 2021-2022 | |
| Nxstage Medical, INC. | $73.85 | 2022 | |
| Allergan, INC. | $72.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.13 | 2025 | |
| Opko Pharmaceuticals, LLC | $57.19 | 2025 | Rayaldee |
| Akebia Therapeutics INC | $54.19 | 2024-2025 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $44.09 | 2025 | Terlivaz |
| Karyopharm Therapeutics INC. | $31.91 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $28.44 | 2019 | |
| Abbvie INC. | $24.18 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.00 | 2019 | |
| Viiv Healthcare Company | $20.96 | 2019 | |
| Shire North American Group INC | $20.48 | 2019 | |
| Apellis Pharmaceuticals, INC. | $19.54 | 2025 | Empaveli |
| Incyte Corporation | $19.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devyani Sivakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.